SlideShare a Scribd company logo
Screening models of
anti-Psychotic
Drugs
1
Department of Pharmacology BVVS COP
BGK
contents
❖Introduction
❖Clinical features of schizophrenia
❖Classification of antipsychotics
❖Pathophysiology of schizophrenia
❖Screening models for antipsychotics
2
Department of Pharmacology BVVS COP
BGK
Introduction
➢Antipsychotic are the drugs having therapeutic
effect in psychoses.
Psychoses
Functional
disorder
Cognitive
disorder
Ex: Schizophrenia Ex: Delirium, Dementia
3
Department of Pharmacology BVVS COP
BGK
Schizophrenia: It is a particular type of psychosis (that is
mental disorder caused by inherent dysfunction of the
brain).
➢ Symptoms are wide ranging and are found across
multiple cultural and ethnic group.
➢ It is characterized by delusions, hallucinations, and
thinking or speech disturbance.
➢Affects 1% of population.
➢Affects young and old.
➢Affects men and women equally.
➢Chronic and disabling disease.
4
Department of Pharmacology BVVS COP
BGK
❖ETIOLOGY
➢Genetic predisposition (10%)
➢ Prenatal (viral infections)
➢Prenatal (oxygen deprivation)
➢Postnatal (CNS infections)
➢Stress in adolescence
5
Department of Pharmacology BVVS COP
BGK
CLINICAL FEATURES
Positive
Symptoms
Negative
symptoms
Cognitive
Symptoms
•Delusions
•Hallucination
•Thought disorders
•Introvert behavior
•Poor socialization
•Emotional blunting
•Lack of attention
•Loss of memory
6
Department of Pharmacology BVVS COP
BGK
Pharmacological classification
➢ First-generation antipsychotic (low potency)
✓ Chlorpromazine
✓ Prochlorperazine
✓ Thioridazine
First generation antipsychotics(high potency)
✓ Fluphenazine
✓ Haloperidol
✓ Pimozide
✓ Thiothixene
➢Second generation antipsychotics
✓ Aripiprazole Olanzapine
✓ Asenapine Paliperidone
✓ Clozapine Risperidone
✓ Iloloperidol Ziprasidone
✓ Lurasidone
7
Department of Pharmacology BVVS COP
BGK
❖PATHOPHYSIOLOGY OF SCHIZOPHRENIA
❖Neurophysiological theory
➢ Dopamine theory
➢ Serotonin theory
➢ Glutamate theory
❖Dopamine theory
➢ Abnormal increase in dopamine
❖Hypo frontal hypothesis:
➢ Increase DA in mesolimbic site of brain
➢ Decrease DA in frontal, pre-frontal & the temporal
❖Cervices → Decrease metabolic activity
❖Other reason are increase serotonin (5HT, glutamate)
8
Department of Pharmacology BVVS COP
BGK
➢The psychosis behaviour mainly occurs due to excessive
release of Dopamine at D2 receptors.
No consistent bio-chemical evidence for excessive
dopamine synthesis or release.
➢The mesolimbic system is a dopaminergic tract that
originates in the ventral tegmental area (VTA) and projects
to the nucleus accumbens, ventral striatum, parts of the
hippocampus, and other components of the limbic system.
➢It involve the development of emotions & memory, and
some hypothesize that mesolimbic hyperactivity is
responsible for the positive symptoms of schizophrenia.
DOPAMINE THEORY
9
Department of Pharmacology BVVS COP
BGK
10
Department of Pharmacology BVVS COP
BGK
11
Department of Pharmacology BVVS COP
BGK
IN VITRO MODELS IN VIVO MODELS
1) D1 receptor assay ³H –SCH 23 390
binding to rat striatal homogenates.
2) D2 receptor assay ³H spiroperidol
binding
3) D2 receptor auto radiography
³H spiperone binding
4) Binding to the D3 and D4 receptor
5) Determination of dopamine auto
receptor activity.
6) α1 adrenergic receptor binding in
brain
7) Serotonin 5HT receptor
autoradiography.
8) Binding to the sigma receptor.
9) Measurement of neurotransmitters
by intracranial micro-dialysis.
10)Simultaneous determination of
nor-epineprine, dopamine, DOPAC,
HVA, 5HIAA.
1) Golden hamster test
2) Influence on behavior of the
cotton rat
3) Open field test
4) Brain self stimulation.
5) Rota rod method
6) Amphetamine group toxicity
7) Inhibition of mouse jumping
8) Pole climb avoidance in rats.
9) Artificial hibernation in rats.
10) Grip strength
12
Department of Pharmacology BVVS COP
BGK
IN VITRO MODELS
➢ D1 Receptor Assay
(³H- SCH 23 390 binding to rat stratial homogenates)
➢D2 Receptor assay
(³H spiroperidol binding)
13
Department of Pharmacology BVVS COP
BGK
PURPOSE AND RATIONAL
➢Dopamine receptor are the primary targets in the development of drugs for the
treatment of schizophrenia, Parkinson’s diseases.
➢Multiple dopamine receptors are know. Designated as D1 and D2.
D1A
D1
DOPAMINE D2B
D2 D2S
D3 D2L
D5 D4
D1 Receptor assay
³H-SCH23390 Binding rat striatal homogenates
14
Department of Pharmacology BVVS COP
BGK
➢For typical neuroleptic agents, Haloperidol, good correlation
was found between D2 receptor binding and clinically
effective doses.
➢A typical neuroleptics, like clozapin, were found to be potent
inhibitors of D1 and D4 receptor binding, renewing interest
in these receptor types.
➢The compound SCH 23390 was found to be selective for
the D1 receptor.
15
Department of Pharmacology BVVS COP
BGK
❖ PROCEDURE
➢REAGENTS:
➢d-Butaclamol a 1 mM stock solution is made and diluted
1:20.
➢ 20 µl are added to 3 tubes for the determination of
nonspecific binding.
➢ For the test compounds a 1 mM stock solution is made
up in a suitable solvents and serially diluted, such that the
final concentration in the assays ranges from 10ˉ⁵ to 10ˉ⁸M.
16
Department of Pharmacology BVVS COP
BGK
❖Tissue preparation
Male Wister rates
decapitated, striate dissected.
Brains rapidly removed and weighed
The striata are homogenized in 100 volumes of 0.05 M tris buffer,
Mantained pH 7.7 using a Tekmar homogenizer.
centrifused at 40,000g for 20 min
The final pellet is re-suspended in the original volume of 0.05M Tris
buffer, pH 7.7, containing physiological ions
(NaCl 120mM, KCl 5mM, MgCI2 1mM and CaCl2 2mM).
17
Department of Pharmacology BVVS COP
BGK
❖ASSAY
➢50µl 0.5 M Tris buffer, pH 7.7, containing physiological
ions. 380µl H₂O, 20µl vehicle or d-butaclamol or
appropriate concentration of test compound.
➢5oµl 3H- SCH23390
➢500µl tissue suspension.
➢ The tubes are incubated at 37ºC for 30 min.
➢The assay is stopped by rapid filtration through
whatman’s GF/B filters using a brand-ell cell harvester.
➢The filter strips are then washed 3 times with ice-cold
0.05M this buffer, pH7.7, and counted in 10ml Liquiscint
scintillation cocktail.
18
Department of Pharmacology BVVS COP
BGK
❖EVALUATION
➢Specific binding is defined as the difference between total
binding in the presence of 1µM d-butaclamol.
➢ IC50 calculations are performed using log-Probit
analysis.
19
Department of Pharmacology BVVS COP
BGK
❖D2 RECEPTOR ASSAY: (³H) spiroperidol binding
❖PURPOSE AND RATIONALE
➢The neuroleptic compound haloperidol has been used as
binding ligand to study the activity of other neuroleptics.
➢ The use of haloperidol has been superseded by
spiroperidol.
➢Dopamine receptor binding assays employing
dopaminergic antagonists in mammalian striatal tissue,
dopamine enriched area of the brain, have been shown to be
predictive of in vivo dopamine receptor antagonism and
antipsychotic activity.
20
Department of Pharmacology BVVS COP
BGK
❖TISSUE PREPARATION
Male rats decapitated
striata removed and weighed
Homogenized in 50 volumes of ice cold 0.05M tris buffer ,
Ph 7.7
Then centrifuged at 40,000g for15 min
Again that pellets were re-centrifuse at 40,000g
Then the final pellets were re-suspended in Tris buffer
(physiological salt) resulting in a concentration of 10mg/ml.
21
Department of Pharmacology BVVS COP
BGK
❖ASSAY
The membrane preparation took
Incubated with ³H spiroperidol (0.25nm) and various concentration of
test drug at 37ºc for 20 min k/Na phosphate buffer.
Cooling in an ice bath for 45min
Bound ligand is separated by rapid filtration
Filters are washed 3 times with ice cold water
Dry it and shaken through with 3.5ml scintillation fluid
From the liquid scintillation counter radio activity is determined.
22
Department of Pharmacology BVVS COP
BGK
❖EVALUATION
From this assay
The following parameters are determined
✓Total binding of ³H spiroperidol
✓Non specific binding: binding of samples containing
2mM butaclamol
✓Specific binding = total binding – non specific binding
✓% inhibition :100- specific binding as % of control value.
23
Department of Pharmacology BVVS COP
BGK
IN VIVO MODELS
➢Open field test
➢Rota road method
➢ Grip strength
24
Department of Pharmacology BVVS COP
BGK
❖Purpose and Rationale:
➢ Interruption of light beams as a measure of movements
of rats and mice in a cage (“open field”).
❖Procedure:
➢ Rats are observed in a square open field equipped with 2
rows of 8 photo cells, sensitive to IR.
➢ The photo cells are placed apart from each other and the
last photo cell in a row is spaced 25mm from the wall.
➢ Measurements are made in a ventilated, sound-
attenuating box.
➢ Interruptions of photocell beams can be collected by
micro-computer as follows
❖OPEN FIELD TEST
25
Department of Pharmacology BVVS COP
BGK
➢Motor activity: All interruptions of photo beams in the
lower rows.
➢Peripheral motor activity: Activation of photo beams in
the lower rows, provided that the photo beams from the wall
were collected.
➢Rearing: All the interruption of the photo beams in the
upper rows.
➢Locomotion: Successive interruptions of photo cells in the
lower rows, when the animal is moving in the same
direction.
➢Speed: The time between successive photo beam
interruptions during locomotion collected in 0.1s categories.
26
Department of Pharmacology BVVS COP
BGK
27
Department of Pharmacology BVVS COP
BGK
❖Evaluation:
➢Dose response curves can be obtained for sedative &
stimulant drugs, whereas the various parameters show
different results.
➢The effects of various drugs are compared statistically
with the values of controls & among themselves.
❖Modifications:
➢Besides interruption of light beams, devices based on
capacitance systems have been developed.
28
Department of Pharmacology BVVS COP
BGK
❖Purpose and Rationale:
➢ The test is used to evaluate the activity of the drugs
interfering with motor co-ordination which suggests that
the skeletal muscle relaxation induced by an compound.
❖Procedure:
➢ Its an horizontal wood or metal rod coat with rubber.
➢ The rod is divided into 6 sections by plastic discs, there by
allowing simultaneous testing of 6 mice.
➢ Rod is placed at an certain height above the table in order to
discourage the animals from jumping off the roller.
➢ Cages, below placed serves to place the animals, whenever
they fell down.
➢ Trained animals are selected. The test compounds are
administered either by oral or i.p.
❖Rota rod Method
29
Department of Pharmacology BVVS COP
BGK
ROTARODAPPARATUS
30
Department of Pharmacology BVVS COP
BGK
➢ Mice are placed on the rod for 1min after administration
of drug.
➢ The number of animals falling down are noted along
with the time.
➢ ED50 is calculated by using different doses.
❖Calculation:
➢ % animals falling from the rota rod with the test period
is calculated for every drug concentration tested.
31
Department of Pharmacology BVVS COP
BGK
❖Grip strength:
❖PURPOSE AND RATIONALE:
➢ The test is being used to assess muscular strength or
Neuromuscular function in rodents.
❖PROCEDURE:
➢ Male or female mice are used.
➢ In a preliminary experiment the animals are tested for
their normal reactivity.
➢ The animals are exposed to a horizontal thin threat or
metallic wire suspended about 30 cm into the air which
they immediately grasp with the forepaws.
➢ The mouse is released to hang on with its forelimbs.
32
Department of Pharmacology BVVS COP
BGK
➢ Normal animals are able to catch the threat with the hind limbs and
to climb up within 5s.
➢ Only animals who fulfil this criterion are included into the
experiment.
➢ Ten mice are used in the control group and in the experimental
groups.
➢ Animals are tested every15 min.
➢ Animals which are not able to touch the threat with the hind limbs
within 5s or fall off from the threat are considered to be impaired.
➢ The test is continued for 2 hrs.
➢ The animals are observed for their behaviour in the cages.
➢ Only if their behaviour and their motility in the cage seem to be
normal the disturbance of the grasping reflex can be considered as
caused by central relaxation.
33
Department of Pharmacology BVVS COP
BGK
34
Department of Pharmacology BVVS COP
BGK
❖References
➢ Drug Discovery & Evaluation Pharmacological assay
– H. G. Vogel
➢ Rang and Dale Pharmacology sixth edition H. P. Rang,
M. M. Dale J. M. Ritter R. J. Flower
➢ Goodman and Gilman`s Manual of Pharmacology and
Therapeutics
35
Department of Pharmacology BVVS COP
BGK
THANK YOU
36
Department of Pharmacology BVVS COP
BGK

More Related Content

What's hot

Anxiolytics screening methods
Anxiolytics screening methodsAnxiolytics screening methods
Anxiolytics screening methods
Saikrishna Komaragiri
 
Screening models of antiepileptic and nootropic drugs
Screening models of antiepileptic and nootropic drugsScreening models of antiepileptic and nootropic drugs
Screening models of antiepileptic and nootropic drugs
HimikaRathi
 
Screening model for asthma COPD
Screening model for asthma COPDScreening model for asthma COPD
Screening model for asthma COPD
Jaineel Dharod
 
Preclinical screening of antiallergics
Preclinical screening of antiallergicsPreclinical screening of antiallergics
Preclinical screening of antiallergics
Prajitha p
 
Preclinical screening of anti anginals
Preclinical screening of anti anginalsPreclinical screening of anti anginals
Preclinical screening of anti anginals
Dekollu Suku
 
Preclinical Screening of Antipsychotic Agents
Preclinical Screening of Antipsychotic Agents Preclinical Screening of Antipsychotic Agents
Preclinical Screening of Antipsychotic Agents
Anurag Chourasia
 
Preclinical Screening for Alzheimer's
Preclinical Screening for Alzheimer'sPreclinical Screening for Alzheimer's
Preclinical Screening for Alzheimer's
Drx Burade
 
Assignment on Preclinical Screening of Immunomodulators
Assignment on Preclinical Screening of ImmunomodulatorsAssignment on Preclinical Screening of Immunomodulators
Assignment on Preclinical Screening of Immunomodulators
Deepak Kumar
 
Screening of anti anxiety drugs
Screening of anti anxiety drugsScreening of anti anxiety drugs
Screening of anti anxiety drugsBindu Pulugurtha
 
In-Vivo & In-Vitro screening of Anti-asthmatic Drug
In-Vivo & In-Vitro screening of Anti-asthmatic Drug In-Vivo & In-Vitro screening of Anti-asthmatic Drug
In-Vivo & In-Vitro screening of Anti-asthmatic Drug
BiplobDey5
 
Screening method of nootropics vikas malik
Screening method of nootropics vikas malikScreening method of nootropics vikas malik
Screening method of nootropics vikas malik
VikasMalik68
 
Screening of antiparkinson agent
Screening of antiparkinson agentScreening of antiparkinson agent
Screening of antiparkinson agent
SONALPANDE5
 
Screening models of Anti diabetics.
Screening models of Anti diabetics.Screening models of Anti diabetics.
Screening Methods of Parkinson's Disease
Screening Methods of Parkinson's DiseaseScreening Methods of Parkinson's Disease
Screening Methods of Parkinson's Disease
Anupam dubey
 
Screening of antiparkinsonian agents
Screening of antiparkinsonian agentsScreening of antiparkinsonian agents
Screening of antiparkinsonian agents
Dr. Mallappa Shalavadi
 
Screening Methods for behavioural and muscle Coordination
 Screening Methods for behavioural and muscle Coordination Screening Methods for behavioural and muscle Coordination
Screening Methods for behavioural and muscle Coordination
pradnya Jagtap
 
Anti epileptic screening model
Anti epileptic screening modelAnti epileptic screening model
Anti epileptic screening model
KhushbooThakur15
 
Preclinical Screening for Neurodegenerative Disease (Multiple Sclerosis)
Preclinical Screening for Neurodegenerative Disease (Multiple Sclerosis)Preclinical Screening for Neurodegenerative Disease (Multiple Sclerosis)
Preclinical Screening for Neurodegenerative Disease (Multiple Sclerosis)
Drx Burade
 
Hepatoprotective screening methods
Hepatoprotective screening methodsHepatoprotective screening methods
Hepatoprotective screening methods
ShobhiniChandel
 
Screening of antidepressant agents
Screening of antidepressant agentsScreening of antidepressant agents
Screening of antidepressant agents
Dr. Partha Sarkar
 

What's hot (20)

Anxiolytics screening methods
Anxiolytics screening methodsAnxiolytics screening methods
Anxiolytics screening methods
 
Screening models of antiepileptic and nootropic drugs
Screening models of antiepileptic and nootropic drugsScreening models of antiepileptic and nootropic drugs
Screening models of antiepileptic and nootropic drugs
 
Screening model for asthma COPD
Screening model for asthma COPDScreening model for asthma COPD
Screening model for asthma COPD
 
Preclinical screening of antiallergics
Preclinical screening of antiallergicsPreclinical screening of antiallergics
Preclinical screening of antiallergics
 
Preclinical screening of anti anginals
Preclinical screening of anti anginalsPreclinical screening of anti anginals
Preclinical screening of anti anginals
 
Preclinical Screening of Antipsychotic Agents
Preclinical Screening of Antipsychotic Agents Preclinical Screening of Antipsychotic Agents
Preclinical Screening of Antipsychotic Agents
 
Preclinical Screening for Alzheimer's
Preclinical Screening for Alzheimer'sPreclinical Screening for Alzheimer's
Preclinical Screening for Alzheimer's
 
Assignment on Preclinical Screening of Immunomodulators
Assignment on Preclinical Screening of ImmunomodulatorsAssignment on Preclinical Screening of Immunomodulators
Assignment on Preclinical Screening of Immunomodulators
 
Screening of anti anxiety drugs
Screening of anti anxiety drugsScreening of anti anxiety drugs
Screening of anti anxiety drugs
 
In-Vivo & In-Vitro screening of Anti-asthmatic Drug
In-Vivo & In-Vitro screening of Anti-asthmatic Drug In-Vivo & In-Vitro screening of Anti-asthmatic Drug
In-Vivo & In-Vitro screening of Anti-asthmatic Drug
 
Screening method of nootropics vikas malik
Screening method of nootropics vikas malikScreening method of nootropics vikas malik
Screening method of nootropics vikas malik
 
Screening of antiparkinson agent
Screening of antiparkinson agentScreening of antiparkinson agent
Screening of antiparkinson agent
 
Screening models of Anti diabetics.
Screening models of Anti diabetics.Screening models of Anti diabetics.
Screening models of Anti diabetics.
 
Screening Methods of Parkinson's Disease
Screening Methods of Parkinson's DiseaseScreening Methods of Parkinson's Disease
Screening Methods of Parkinson's Disease
 
Screening of antiparkinsonian agents
Screening of antiparkinsonian agentsScreening of antiparkinsonian agents
Screening of antiparkinsonian agents
 
Screening Methods for behavioural and muscle Coordination
 Screening Methods for behavioural and muscle Coordination Screening Methods for behavioural and muscle Coordination
Screening Methods for behavioural and muscle Coordination
 
Anti epileptic screening model
Anti epileptic screening modelAnti epileptic screening model
Anti epileptic screening model
 
Preclinical Screening for Neurodegenerative Disease (Multiple Sclerosis)
Preclinical Screening for Neurodegenerative Disease (Multiple Sclerosis)Preclinical Screening for Neurodegenerative Disease (Multiple Sclerosis)
Preclinical Screening for Neurodegenerative Disease (Multiple Sclerosis)
 
Hepatoprotective screening methods
Hepatoprotective screening methodsHepatoprotective screening methods
Hepatoprotective screening methods
 
Screening of antidepressant agents
Screening of antidepressant agentsScreening of antidepressant agents
Screening of antidepressant agents
 

Similar to Screening models of anti psychotic drugs-converted

Drug evaluation for parkinson's disease 04-01-2020
Drug evaluation for parkinson's disease  04-01-2020Drug evaluation for parkinson's disease  04-01-2020
Drug evaluation for parkinson's disease 04-01-2020
Seth GSMC and KEM Municipal Hospital
 
Alzheimer models
Alzheimer modelsAlzheimer models
Alzheimer models
Mohammad Muztaba
 
Preclinical study of anti parkinsonian drugs
Preclinical study of anti  parkinsonian drugsPreclinical study of anti  parkinsonian drugs
Preclinical study of anti parkinsonian drugs
HinnaHamid1
 
piracetam and vinpocetine ameliorate rotenone induced parkinsonism in rats.
piracetam and vinpocetine ameliorate  rotenone induced parkinsonism in rats.piracetam and vinpocetine ameliorate  rotenone induced parkinsonism in rats.
piracetam and vinpocetine ameliorate rotenone induced parkinsonism in rats.
SANJAY YADAV
 
Screening models of cns stimulant & anti depressant drugs-converted
Screening models of cns stimulant & anti depressant drugs-convertedScreening models of cns stimulant & anti depressant drugs-converted
Screening models of cns stimulant & anti depressant drugs-converted
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
Antipsychotic screening models
Antipsychotic screening modelsAntipsychotic screening models
Antipsychotic screening models
InnocentAmubwine
 
Preclinical Screening for Neurodegenerative Disease (Parkinsonism)
Preclinical Screening for Neurodegenerative Disease (Parkinsonism)Preclinical Screening for Neurodegenerative Disease (Parkinsonism)
Preclinical Screening for Neurodegenerative Disease (Parkinsonism)
Drx Burade
 
Screening Models for Parkinson's Disease ppt
Screening Models  for Parkinson's Disease pptScreening Models  for Parkinson's Disease ppt
Screening Models for Parkinson's Disease ppt
SanskritiUpadhyay5
 
Screening of antiparkinsons drug by kahkesha (3)
Screening of antiparkinsons drug  by kahkesha (3)Screening of antiparkinsons drug  by kahkesha (3)
Screening of antiparkinsons drug by kahkesha (3)
kahkesha samshad
 
NEURODEGENERATIVE DISEASE
NEURODEGENERATIVE DISEASENEURODEGENERATIVE DISEASE
NEURODEGENERATIVE DISEASE
ANAND SAGAR TIWARI
 
anti parkinson screening model .pptx
anti parkinson  screening model    .pptxanti parkinson  screening model    .pptx
anti parkinson screening model .pptx
NittalVekaria
 
screening of ans drugs
screening of ans drugsscreening of ans drugs
screening of ans drugsSrota Dawn
 
Anxiolytic drugs : important
Anxiolytic drugs : importantAnxiolytic drugs : important
Anxiolytic drugs : important
rx_sonali
 
Screening Models of Antipsychotic Drugs - Devendra Kumar Mishra
Screening Models of Antipsychotic Drugs - Devendra Kumar MishraScreening Models of Antipsychotic Drugs - Devendra Kumar Mishra
Screening Models of Antipsychotic Drugs - Devendra Kumar Mishra
DEVENDRA KUMAR MISHRA
 
Screening methos for ans drugs
Screening methos for ans drugsScreening methos for ans drugs
Screening methos for ans drugs
Dineshk117
 
Neuroscience Letters
Neuroscience LettersNeuroscience Letters
Neuroscience Letters
Piter Pen
 
Evaluation of Anti-Epileptic Drugs
Evaluation of Anti-Epileptic DrugsEvaluation of Anti-Epileptic Drugs
Evaluation of Anti-Epileptic Drugs
Dr. Shivesh Gupta
 
Kishan singh
Kishan singhKishan singh
Kishan singh
Kishan Singh
 

Similar to Screening models of anti psychotic drugs-converted (20)

Drug evaluation for parkinson's disease 04-01-2020
Drug evaluation for parkinson's disease  04-01-2020Drug evaluation for parkinson's disease  04-01-2020
Drug evaluation for parkinson's disease 04-01-2020
 
Alzheimer models
Alzheimer modelsAlzheimer models
Alzheimer models
 
Preclinical study of anti parkinsonian drugs
Preclinical study of anti  parkinsonian drugsPreclinical study of anti  parkinsonian drugs
Preclinical study of anti parkinsonian drugs
 
piracetam and vinpocetine ameliorate rotenone induced parkinsonism in rats.
piracetam and vinpocetine ameliorate  rotenone induced parkinsonism in rats.piracetam and vinpocetine ameliorate  rotenone induced parkinsonism in rats.
piracetam and vinpocetine ameliorate rotenone induced parkinsonism in rats.
 
Screening models of cns stimulant & anti depressant drugs-converted
Screening models of cns stimulant & anti depressant drugs-convertedScreening models of cns stimulant & anti depressant drugs-converted
Screening models of cns stimulant & anti depressant drugs-converted
 
Antipsychotic screening models
Antipsychotic screening modelsAntipsychotic screening models
Antipsychotic screening models
 
Preclinical Screening for Neurodegenerative Disease (Parkinsonism)
Preclinical Screening for Neurodegenerative Disease (Parkinsonism)Preclinical Screening for Neurodegenerative Disease (Parkinsonism)
Preclinical Screening for Neurodegenerative Disease (Parkinsonism)
 
Screening Models for Parkinson's Disease ppt
Screening Models  for Parkinson's Disease pptScreening Models  for Parkinson's Disease ppt
Screening Models for Parkinson's Disease ppt
 
Epilesy
EpilesyEpilesy
Epilesy
 
Screening of antiparkinsons drug by kahkesha (3)
Screening of antiparkinsons drug  by kahkesha (3)Screening of antiparkinsons drug  by kahkesha (3)
Screening of antiparkinsons drug by kahkesha (3)
 
NEURODEGENERATIVE DISEASE
NEURODEGENERATIVE DISEASENEURODEGENERATIVE DISEASE
NEURODEGENERATIVE DISEASE
 
Screening models of alzheimer disease
Screening models of alzheimer diseaseScreening models of alzheimer disease
Screening models of alzheimer disease
 
anti parkinson screening model .pptx
anti parkinson  screening model    .pptxanti parkinson  screening model    .pptx
anti parkinson screening model .pptx
 
screening of ans drugs
screening of ans drugsscreening of ans drugs
screening of ans drugs
 
Anxiolytic drugs : important
Anxiolytic drugs : importantAnxiolytic drugs : important
Anxiolytic drugs : important
 
Screening Models of Antipsychotic Drugs - Devendra Kumar Mishra
Screening Models of Antipsychotic Drugs - Devendra Kumar MishraScreening Models of Antipsychotic Drugs - Devendra Kumar Mishra
Screening Models of Antipsychotic Drugs - Devendra Kumar Mishra
 
Screening methos for ans drugs
Screening methos for ans drugsScreening methos for ans drugs
Screening methos for ans drugs
 
Neuroscience Letters
Neuroscience LettersNeuroscience Letters
Neuroscience Letters
 
Evaluation of Anti-Epileptic Drugs
Evaluation of Anti-Epileptic DrugsEvaluation of Anti-Epileptic Drugs
Evaluation of Anti-Epileptic Drugs
 
Kishan singh
Kishan singhKishan singh
Kishan singh
 

More from B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote

Seminr on overview of drug discovery and development converted
Seminr on overview of drug discovery and development convertedSeminr on overview of drug discovery and development converted
Seminr on overview of drug discovery and development converted
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
Seminor on molecular & cellular moa of thyriod harmone and insulin converted
Seminor on molecular & cellular moa of thyriod  harmone and insulin convertedSeminor on molecular & cellular moa of thyriod  harmone and insulin converted
Seminor on molecular & cellular moa of thyriod harmone and insulin converted
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
Seminar on protein and protein structure
Seminar on protein and protein structureSeminar on protein and protein structure
Seminar on protein and protein structure
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
Seminar on parasympathomimetic and parasympatholytic converted
Seminar on parasympathomimetic and parasympatholytic convertedSeminar on parasympathomimetic and parasympatholytic converted
Seminar on parasympathomimetic and parasympatholytic converted
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
Seminar on antisense technology and antisense oligonucleotides converted
Seminar on antisense technology and antisense oligonucleotides convertedSeminar on antisense technology and antisense oligonucleotides converted
Seminar on antisense technology and antisense oligonucleotides converted
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
Screening models on behavioral and muscle coordination converted
Screening models on behavioral and muscle coordination convertedScreening models on behavioral and muscle coordination converted
Screening models on behavioral and muscle coordination converted
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
Presentation on sex harmones converted
Presentation on sex harmones convertedPresentation on sex harmones converted
Presentation on rational drug design converted
Presentation on rational drug design convertedPresentation on rational drug design converted
Presentation on rational drug design converted
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
Presentation on neurotransmitter’s on dopamine and gaba converted (1)
Presentation on neurotransmitter’s on dopamine and gaba converted (1)Presentation on neurotransmitter’s on dopamine and gaba converted (1)
Presentation on neurotransmitter’s on dopamine and gaba converted (1)
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
Presentation on neurotransmitter’s acetylcholine and adrenaline converted
Presentation on neurotransmitter’s acetylcholine and adrenaline convertedPresentation on neurotransmitter’s acetylcholine and adrenaline converted
Presentation on neurotransmitter’s acetylcholine and adrenaline converted
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
Presentation on neurotransmission and noradrealine norcholinergic (nanc) conv...
Presentation on neurotransmission and noradrealine norcholinergic (nanc) conv...Presentation on neurotransmission and noradrealine norcholinergic (nanc) conv...
Presentation on neurotransmission and noradrealine norcholinergic (nanc) conv...
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
Presentation on growth harmone and prolactin converted
Presentation on growth harmone and prolactin convertedPresentation on growth harmone and prolactin converted
Presentation on growth harmone and prolactin converted
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
Presentation on concept of pharmacophore mapping and pharmacophore based scre...
Presentation on concept of pharmacophore mapping and pharmacophore based scre...Presentation on concept of pharmacophore mapping and pharmacophore based scre...
Presentation on concept of pharmacophore mapping and pharmacophore based scre...
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
Presentation on antiviral agent’s
Presentation on antiviral agent’sPresentation on antiviral agent’s
Presentation on antifungal agents converted
Presentation on antifungal agents convertedPresentation on antifungal agents converted
Presentation on antifungal agents converted
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 
Presenatation on insillico drug design
Presenatation on insillico drug designPresenatation on insillico drug design
Role of genomics proteomics, and bioinformatics.
Role of genomics proteomics, and bioinformatics.Role of genomics proteomics, and bioinformatics.
Role of genomics proteomics, and bioinformatics.
B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote
 

More from B V V S Hanagal Shri Kumareshwar College of Pharmacy, Bagalkote (20)

Seminr on overview of drug discovery and development converted
Seminr on overview of drug discovery and development convertedSeminr on overview of drug discovery and development converted
Seminr on overview of drug discovery and development converted
 
Seminor on molecular & cellular moa of thyriod harmone and insulin converted
Seminor on molecular & cellular moa of thyriod  harmone and insulin convertedSeminor on molecular & cellular moa of thyriod  harmone and insulin converted
Seminor on molecular & cellular moa of thyriod harmone and insulin converted
 
Seminar on protein and protein structure
Seminar on protein and protein structureSeminar on protein and protein structure
Seminar on protein and protein structure
 
Seminar on pharmacokinetics
Seminar on pharmacokineticsSeminar on pharmacokinetics
Seminar on pharmacokinetics
 
Seminar on parasympathomimetic and parasympatholytic converted
Seminar on parasympathomimetic and parasympatholytic convertedSeminar on parasympathomimetic and parasympatholytic converted
Seminar on parasympathomimetic and parasympatholytic converted
 
Seminar on antisense technology and antisense oligonucleotides converted
Seminar on antisense technology and antisense oligonucleotides convertedSeminar on antisense technology and antisense oligonucleotides converted
Seminar on antisense technology and antisense oligonucleotides converted
 
Screening models on behavioral and muscle coordination converted
Screening models on behavioral and muscle coordination convertedScreening models on behavioral and muscle coordination converted
Screening models on behavioral and muscle coordination converted
 
Presentation on sex harmones converted
Presentation on sex harmones convertedPresentation on sex harmones converted
Presentation on sex harmones converted
 
Presentation on rational drug design converted
Presentation on rational drug design convertedPresentation on rational drug design converted
Presentation on rational drug design converted
 
Presentation on neurotransmitter’s on dopamine and gaba converted (1)
Presentation on neurotransmitter’s on dopamine and gaba converted (1)Presentation on neurotransmitter’s on dopamine and gaba converted (1)
Presentation on neurotransmitter’s on dopamine and gaba converted (1)
 
Presentation on neurotransmitter’s acetylcholine and adrenaline converted
Presentation on neurotransmitter’s acetylcholine and adrenaline convertedPresentation on neurotransmitter’s acetylcholine and adrenaline converted
Presentation on neurotransmitter’s acetylcholine and adrenaline converted
 
Presentation on neurotransmission and noradrealine norcholinergic (nanc) conv...
Presentation on neurotransmission and noradrealine norcholinergic (nanc) conv...Presentation on neurotransmission and noradrealine norcholinergic (nanc) conv...
Presentation on neurotransmission and noradrealine norcholinergic (nanc) conv...
 
Presentation on growth harmone and prolactin converted
Presentation on growth harmone and prolactin convertedPresentation on growth harmone and prolactin converted
Presentation on growth harmone and prolactin converted
 
Presentation on concept of pharmacophore mapping and pharmacophore based scre...
Presentation on concept of pharmacophore mapping and pharmacophore based scre...Presentation on concept of pharmacophore mapping and pharmacophore based scre...
Presentation on concept of pharmacophore mapping and pharmacophore based scre...
 
Presentation on antiviral agent’s
Presentation on antiviral agent’sPresentation on antiviral agent’s
Presentation on antiviral agent’s
 
Presentation on antifungal agents converted
Presentation on antifungal agents convertedPresentation on antifungal agents converted
Presentation on antifungal agents converted
 
Presenatation on insillico drug design
Presenatation on insillico drug designPresenatation on insillico drug design
Presenatation on insillico drug design
 
Good laboratory practice
Good laboratory practiceGood laboratory practice
Good laboratory practice
 
Chemotheraphy of cancer
Chemotheraphy of cancerChemotheraphy of cancer
Chemotheraphy of cancer
 
Role of genomics proteomics, and bioinformatics.
Role of genomics proteomics, and bioinformatics.Role of genomics proteomics, and bioinformatics.
Role of genomics proteomics, and bioinformatics.
 

Recently uploaded

Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
Nguyen Thanh Tu Collection
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
TechSoup
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
Peter Windle
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
BhavyaRajput3
 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
Tamralipta Mahavidyalaya
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
Atul Kumar Singh
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
SACHIN R KONDAGURI
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
 

Recently uploaded (20)

Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
 

Screening models of anti psychotic drugs-converted

  • 2. contents ❖Introduction ❖Clinical features of schizophrenia ❖Classification of antipsychotics ❖Pathophysiology of schizophrenia ❖Screening models for antipsychotics 2 Department of Pharmacology BVVS COP BGK
  • 3. Introduction ➢Antipsychotic are the drugs having therapeutic effect in psychoses. Psychoses Functional disorder Cognitive disorder Ex: Schizophrenia Ex: Delirium, Dementia 3 Department of Pharmacology BVVS COP BGK
  • 4. Schizophrenia: It is a particular type of psychosis (that is mental disorder caused by inherent dysfunction of the brain). ➢ Symptoms are wide ranging and are found across multiple cultural and ethnic group. ➢ It is characterized by delusions, hallucinations, and thinking or speech disturbance. ➢Affects 1% of population. ➢Affects young and old. ➢Affects men and women equally. ➢Chronic and disabling disease. 4 Department of Pharmacology BVVS COP BGK
  • 5. ❖ETIOLOGY ➢Genetic predisposition (10%) ➢ Prenatal (viral infections) ➢Prenatal (oxygen deprivation) ➢Postnatal (CNS infections) ➢Stress in adolescence 5 Department of Pharmacology BVVS COP BGK
  • 6. CLINICAL FEATURES Positive Symptoms Negative symptoms Cognitive Symptoms •Delusions •Hallucination •Thought disorders •Introvert behavior •Poor socialization •Emotional blunting •Lack of attention •Loss of memory 6 Department of Pharmacology BVVS COP BGK
  • 7. Pharmacological classification ➢ First-generation antipsychotic (low potency) ✓ Chlorpromazine ✓ Prochlorperazine ✓ Thioridazine First generation antipsychotics(high potency) ✓ Fluphenazine ✓ Haloperidol ✓ Pimozide ✓ Thiothixene ➢Second generation antipsychotics ✓ Aripiprazole Olanzapine ✓ Asenapine Paliperidone ✓ Clozapine Risperidone ✓ Iloloperidol Ziprasidone ✓ Lurasidone 7 Department of Pharmacology BVVS COP BGK
  • 8. ❖PATHOPHYSIOLOGY OF SCHIZOPHRENIA ❖Neurophysiological theory ➢ Dopamine theory ➢ Serotonin theory ➢ Glutamate theory ❖Dopamine theory ➢ Abnormal increase in dopamine ❖Hypo frontal hypothesis: ➢ Increase DA in mesolimbic site of brain ➢ Decrease DA in frontal, pre-frontal & the temporal ❖Cervices → Decrease metabolic activity ❖Other reason are increase serotonin (5HT, glutamate) 8 Department of Pharmacology BVVS COP BGK
  • 9. ➢The psychosis behaviour mainly occurs due to excessive release of Dopamine at D2 receptors. No consistent bio-chemical evidence for excessive dopamine synthesis or release. ➢The mesolimbic system is a dopaminergic tract that originates in the ventral tegmental area (VTA) and projects to the nucleus accumbens, ventral striatum, parts of the hippocampus, and other components of the limbic system. ➢It involve the development of emotions & memory, and some hypothesize that mesolimbic hyperactivity is responsible for the positive symptoms of schizophrenia. DOPAMINE THEORY 9 Department of Pharmacology BVVS COP BGK
  • 12. IN VITRO MODELS IN VIVO MODELS 1) D1 receptor assay ³H –SCH 23 390 binding to rat striatal homogenates. 2) D2 receptor assay ³H spiroperidol binding 3) D2 receptor auto radiography ³H spiperone binding 4) Binding to the D3 and D4 receptor 5) Determination of dopamine auto receptor activity. 6) α1 adrenergic receptor binding in brain 7) Serotonin 5HT receptor autoradiography. 8) Binding to the sigma receptor. 9) Measurement of neurotransmitters by intracranial micro-dialysis. 10)Simultaneous determination of nor-epineprine, dopamine, DOPAC, HVA, 5HIAA. 1) Golden hamster test 2) Influence on behavior of the cotton rat 3) Open field test 4) Brain self stimulation. 5) Rota rod method 6) Amphetamine group toxicity 7) Inhibition of mouse jumping 8) Pole climb avoidance in rats. 9) Artificial hibernation in rats. 10) Grip strength 12 Department of Pharmacology BVVS COP BGK
  • 13. IN VITRO MODELS ➢ D1 Receptor Assay (³H- SCH 23 390 binding to rat stratial homogenates) ➢D2 Receptor assay (³H spiroperidol binding) 13 Department of Pharmacology BVVS COP BGK
  • 14. PURPOSE AND RATIONAL ➢Dopamine receptor are the primary targets in the development of drugs for the treatment of schizophrenia, Parkinson’s diseases. ➢Multiple dopamine receptors are know. Designated as D1 and D2. D1A D1 DOPAMINE D2B D2 D2S D3 D2L D5 D4 D1 Receptor assay ³H-SCH23390 Binding rat striatal homogenates 14 Department of Pharmacology BVVS COP BGK
  • 15. ➢For typical neuroleptic agents, Haloperidol, good correlation was found between D2 receptor binding and clinically effective doses. ➢A typical neuroleptics, like clozapin, were found to be potent inhibitors of D1 and D4 receptor binding, renewing interest in these receptor types. ➢The compound SCH 23390 was found to be selective for the D1 receptor. 15 Department of Pharmacology BVVS COP BGK
  • 16. ❖ PROCEDURE ➢REAGENTS: ➢d-Butaclamol a 1 mM stock solution is made and diluted 1:20. ➢ 20 µl are added to 3 tubes for the determination of nonspecific binding. ➢ For the test compounds a 1 mM stock solution is made up in a suitable solvents and serially diluted, such that the final concentration in the assays ranges from 10ˉ⁵ to 10ˉ⁸M. 16 Department of Pharmacology BVVS COP BGK
  • 17. ❖Tissue preparation Male Wister rates decapitated, striate dissected. Brains rapidly removed and weighed The striata are homogenized in 100 volumes of 0.05 M tris buffer, Mantained pH 7.7 using a Tekmar homogenizer. centrifused at 40,000g for 20 min The final pellet is re-suspended in the original volume of 0.05M Tris buffer, pH 7.7, containing physiological ions (NaCl 120mM, KCl 5mM, MgCI2 1mM and CaCl2 2mM). 17 Department of Pharmacology BVVS COP BGK
  • 18. ❖ASSAY ➢50µl 0.5 M Tris buffer, pH 7.7, containing physiological ions. 380µl H₂O, 20µl vehicle or d-butaclamol or appropriate concentration of test compound. ➢5oµl 3H- SCH23390 ➢500µl tissue suspension. ➢ The tubes are incubated at 37ºC for 30 min. ➢The assay is stopped by rapid filtration through whatman’s GF/B filters using a brand-ell cell harvester. ➢The filter strips are then washed 3 times with ice-cold 0.05M this buffer, pH7.7, and counted in 10ml Liquiscint scintillation cocktail. 18 Department of Pharmacology BVVS COP BGK
  • 19. ❖EVALUATION ➢Specific binding is defined as the difference between total binding in the presence of 1µM d-butaclamol. ➢ IC50 calculations are performed using log-Probit analysis. 19 Department of Pharmacology BVVS COP BGK
  • 20. ❖D2 RECEPTOR ASSAY: (³H) spiroperidol binding ❖PURPOSE AND RATIONALE ➢The neuroleptic compound haloperidol has been used as binding ligand to study the activity of other neuroleptics. ➢ The use of haloperidol has been superseded by spiroperidol. ➢Dopamine receptor binding assays employing dopaminergic antagonists in mammalian striatal tissue, dopamine enriched area of the brain, have been shown to be predictive of in vivo dopamine receptor antagonism and antipsychotic activity. 20 Department of Pharmacology BVVS COP BGK
  • 21. ❖TISSUE PREPARATION Male rats decapitated striata removed and weighed Homogenized in 50 volumes of ice cold 0.05M tris buffer , Ph 7.7 Then centrifuged at 40,000g for15 min Again that pellets were re-centrifuse at 40,000g Then the final pellets were re-suspended in Tris buffer (physiological salt) resulting in a concentration of 10mg/ml. 21 Department of Pharmacology BVVS COP BGK
  • 22. ❖ASSAY The membrane preparation took Incubated with ³H spiroperidol (0.25nm) and various concentration of test drug at 37ºc for 20 min k/Na phosphate buffer. Cooling in an ice bath for 45min Bound ligand is separated by rapid filtration Filters are washed 3 times with ice cold water Dry it and shaken through with 3.5ml scintillation fluid From the liquid scintillation counter radio activity is determined. 22 Department of Pharmacology BVVS COP BGK
  • 23. ❖EVALUATION From this assay The following parameters are determined ✓Total binding of ³H spiroperidol ✓Non specific binding: binding of samples containing 2mM butaclamol ✓Specific binding = total binding – non specific binding ✓% inhibition :100- specific binding as % of control value. 23 Department of Pharmacology BVVS COP BGK
  • 24. IN VIVO MODELS ➢Open field test ➢Rota road method ➢ Grip strength 24 Department of Pharmacology BVVS COP BGK
  • 25. ❖Purpose and Rationale: ➢ Interruption of light beams as a measure of movements of rats and mice in a cage (“open field”). ❖Procedure: ➢ Rats are observed in a square open field equipped with 2 rows of 8 photo cells, sensitive to IR. ➢ The photo cells are placed apart from each other and the last photo cell in a row is spaced 25mm from the wall. ➢ Measurements are made in a ventilated, sound- attenuating box. ➢ Interruptions of photocell beams can be collected by micro-computer as follows ❖OPEN FIELD TEST 25 Department of Pharmacology BVVS COP BGK
  • 26. ➢Motor activity: All interruptions of photo beams in the lower rows. ➢Peripheral motor activity: Activation of photo beams in the lower rows, provided that the photo beams from the wall were collected. ➢Rearing: All the interruption of the photo beams in the upper rows. ➢Locomotion: Successive interruptions of photo cells in the lower rows, when the animal is moving in the same direction. ➢Speed: The time between successive photo beam interruptions during locomotion collected in 0.1s categories. 26 Department of Pharmacology BVVS COP BGK
  • 28. ❖Evaluation: ➢Dose response curves can be obtained for sedative & stimulant drugs, whereas the various parameters show different results. ➢The effects of various drugs are compared statistically with the values of controls & among themselves. ❖Modifications: ➢Besides interruption of light beams, devices based on capacitance systems have been developed. 28 Department of Pharmacology BVVS COP BGK
  • 29. ❖Purpose and Rationale: ➢ The test is used to evaluate the activity of the drugs interfering with motor co-ordination which suggests that the skeletal muscle relaxation induced by an compound. ❖Procedure: ➢ Its an horizontal wood or metal rod coat with rubber. ➢ The rod is divided into 6 sections by plastic discs, there by allowing simultaneous testing of 6 mice. ➢ Rod is placed at an certain height above the table in order to discourage the animals from jumping off the roller. ➢ Cages, below placed serves to place the animals, whenever they fell down. ➢ Trained animals are selected. The test compounds are administered either by oral or i.p. ❖Rota rod Method 29 Department of Pharmacology BVVS COP BGK
  • 31. ➢ Mice are placed on the rod for 1min after administration of drug. ➢ The number of animals falling down are noted along with the time. ➢ ED50 is calculated by using different doses. ❖Calculation: ➢ % animals falling from the rota rod with the test period is calculated for every drug concentration tested. 31 Department of Pharmacology BVVS COP BGK
  • 32. ❖Grip strength: ❖PURPOSE AND RATIONALE: ➢ The test is being used to assess muscular strength or Neuromuscular function in rodents. ❖PROCEDURE: ➢ Male or female mice are used. ➢ In a preliminary experiment the animals are tested for their normal reactivity. ➢ The animals are exposed to a horizontal thin threat or metallic wire suspended about 30 cm into the air which they immediately grasp with the forepaws. ➢ The mouse is released to hang on with its forelimbs. 32 Department of Pharmacology BVVS COP BGK
  • 33. ➢ Normal animals are able to catch the threat with the hind limbs and to climb up within 5s. ➢ Only animals who fulfil this criterion are included into the experiment. ➢ Ten mice are used in the control group and in the experimental groups. ➢ Animals are tested every15 min. ➢ Animals which are not able to touch the threat with the hind limbs within 5s or fall off from the threat are considered to be impaired. ➢ The test is continued for 2 hrs. ➢ The animals are observed for their behaviour in the cages. ➢ Only if their behaviour and their motility in the cage seem to be normal the disturbance of the grasping reflex can be considered as caused by central relaxation. 33 Department of Pharmacology BVVS COP BGK
  • 35. ❖References ➢ Drug Discovery & Evaluation Pharmacological assay – H. G. Vogel ➢ Rang and Dale Pharmacology sixth edition H. P. Rang, M. M. Dale J. M. Ritter R. J. Flower ➢ Goodman and Gilman`s Manual of Pharmacology and Therapeutics 35 Department of Pharmacology BVVS COP BGK
  • 36. THANK YOU 36 Department of Pharmacology BVVS COP BGK